CoChat
Sign Up
Cited by 151Lung Cancer Treatments and MutationsCancer Genomics and DiagnosticsLung Cancer Research Studies

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma

Open access
Kim, Seok-Young, Kim, Sang-Min, Lim, Sumin, Lee, Ji Yeon, Choi, Su-Jin, Yang, San-Duk, Yun, Mi Ran, Kim, Chang Gon, Gu, Seo Rin, Park, Chaewon, Park, A-Young, Lim, Sun Min, Heo, Seong Gu, Kim, HyunKi, Cho, Byoung Chul·2021·Clinical Cancer Research
DOI 10.1158/1078-0432.ccr-20-5026PMC PMC9401503

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

Purpose: Patient-derived organoids (PDO) of lung cancer has been recently introduced, reflecting the genomic landscape of lung cancer. However, clinical relevance of advanced lung adenocarcinoma organoids remains unknown. Here, we examined the ability of PDOs to predict clinical responses to targeted therapies in individual patients and to identify effective anticancer therapies for novel molecular targets. Experimental Design: Eighty-four organoids were established from patients with advanced lung adenocarcinoma. Formalin-fixed, paraffin-embedded tumor specimens from corresponding patients were analyzed by whole-exome sequencing (n = 12). Organoids were analyzed by whole-exome sequencing (n = 61) and RNA sequencing (n = 55). Responses to mono or combination targeted therapies were examined in organoids and organoid-derived xenografts. Results: PDOs largely retained somatic alterations including driver mutations of matching patient tumors. PDOs were able to recapitulate progression-free survival and objective responses of patients with non–small cell lung cancer receiving clinically approved tyrosine kinase inhibitors. PDOs recapitulated activity of therapeutic strategies under clinical investigation. YUO-071 harboring an EGFR exon 19 deletion and a BRAF G464A mutation and the matching patient responded to dabrafenib/trametinib combination therapy. YUO-004 and YUO-050 harboring an EGFR L747P mutation was sensitive to afatinib, consistent with the response in the matching patient of YUO-050. Furthermore, we utilized organoids to identify effective therapies for novel molecular targets by demonstrating the efficacy of poziotinib against ERBB2 exon 20 insertions and pralsetinib against RET fusions. Conclusions: We demonstrated translational relevance of PDOs in advanced lung adenocarcinoma. PDOs are an important diagnostic tool, which can assist clinical decision making and accelerate development of therapeutic strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-20-5026

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Establishment and characterization of patient-derived organoids from advanced lung adenocarcinoma. A, Representative H&E and IHC stained images of NSCLC organoids and their parental tumor tissues. The tumor organoids were positive for TTF-1, an adenocarcinoma marker, and negative for Calrectinin, a mesothelial cell marker. NSCLC organoids recapitulated morphologic and histologic features of original tumor tissues. H&E, brightfield, and IHC images are shown. Scale bar, 100 μm. B, Genomic landscape in 61 patient-derived organoids of advanced lung adenocarcinoma. Organoids were derived from TKI-naïve NSCLC, TKI-resistant NSCLC, NSCLC without driver oncogenes, and normal tissue. Clinically relevant somatic alterations selected from the TARGET database are shown. Actionable targets and clinically relevant driver genes based on the NCCN guideline (version 8.2020) and the lung adenocarcinoma TCGA database are indicated (left). Type of alteration is indicated by color codes. The percentage of organoids harboring the indicated alterations are shown (right).
Figure 1. Establishment and characterization of patient-derived organoids from advanced lung adenocarcinoma. A, Representative H&E and IHC stained images of NSCLC organoids and their parental tumor tissues. The tumor organoids were positive for TTF-1, an adenocarcinoma marker, and negative for Calrectinin, a mesothelial cell marker. NSCLC organoids recapitulated morphologic and histologic features of original tumor tissues. H&E, brightfield, and IHC images are shown. Scale bar, 100 μm. B, Genomic landscape in 61 patient-derived organoids of advanced lung adenocarcinoma. Organoids were derived from TKI-naïve NSCLC, TKI-resistant NSCLC, NSCLC without driver oncogenes, and normal tissue. Clinically relevant somatic alterations selected from the TARGET database are shown. Actionable targets and clinically relevant driver genes based on the NCCN guideline (version 8.2020) and the lung adenocarcinoma TCGA database are indicated (left). Type of alteration is indicated by color codes. The percentage of organoids harboring the indicated alterations are shown (right).CC BY-NC-ND · PubMed Central
Figure 2. Advanced lung adenocarcinoma organoids can predict patient treatment responses to a TKI monotherapy. A, Swimmers' plot showing clinical annotations of 9 patients with NSCLC who received subsequent TKI therapy after their tumor specimens were obtained to generate organoids. Each bar represents an individual patient. Subsequent TKI therapy each patient received is indicated on the right. B, Supplementary Table summarizing correlations between clinical responses (PFS) in patients and in vitro responses (mean IC50 value from three independent experiments at 3 days) in matching PDOs. C, Bar graphs showing percentage change of cell viability in PDOs after exposure to each TKI at 100 nmol/L for 3 days. Bar colors represent each patient whose best response was stable disease (red) or partial response (blue) to the TKI. Data are presented as the mean ± SEM (n = 3). PR, partial response; SD, stable disease. See also Supplementary Table S2.
Figure 2. Advanced lung adenocarcinoma organoids can predict patient treatment responses to a TKI monotherapy. A, Swimmers' plot showing clinical annotations of 9 patients with NSCLC who received subsequent TKI therapy after their tumor specimens were obtained to generate organoids. Each bar represents an individual patient. Subsequent TKI therapy each patient received is indicated on the right. B, Supplementary Table summarizing correlations between clinical responses (PFS) in patients and in vitro responses (mean IC50 value from three independent experiments at 3 days) in matching PDOs. C, Bar graphs showing percentage change of cell viability in PDOs after exposure to each TKI at 100 nmol/L for 3 days. Bar colors represent each patient whose best response was stable disease (red) or partial response (blue) to the TKI. Data are presented as the mean ± SEM (n = 3). PR, partial response; SD, stable disease. See also Supplementary Table S2.CC BY-NC-ND · PubMed Central
Figure 3. Drug sensitivity to gefitinib is associated with culture condition in YUO-004. A, Procedure for generating 2D PDOs. 3D PDOs were plated on collagen-coated plates and cultured in AO medium for more than a week up to 4 weeks. B, Comparison of IC50 values to each TKI (top) between 3D and 2D PDOs (two-tailed Student t test: n.s., not significant; **, P < 0.01; ***, P < 0.005). Red line denotes sensitive (IC50 value < 100 nmol/L) or resistant (IC50 value > 100 nmol/L) response to a drug. C, DNA chromatograms showing EGFR L747P mutation in 3D culture and 2D culture of YUO-050 and YUO-004. D, Scheme for model switching. 2D PDOs that were maintained as monolayer less than 4 weeks were switched to 3D culture condition and cultured for up to 4 weeks. All models were maintained in AO medium. E, 3D, 2D, and 2D–3D cultures of YUO-050 and YUO-004 were treated with the indicated concentrations of gefitinib for 3 days. IC50 value of gefitinib is indicated for each culture condition (top). F, Representative immunoblots of indicated molecules in YUO-050 and YUO-004 at baseline. G, Representative immunoblots of indicated molecules in YUO-050 and YUO-004 at baseline. H, 3D YUO-050 and YUO-004 were treated with dasatinib alone, gefitinib alone, or gefitinib in combination with the indicated concentrations of dasatinib for 3 days. I, Representative immunoblots of indicated molecules in YUO-004 treated with the indicated concentration of gefitinib with or without dasatinib. In B, E, and H, data are presented as the mean ± SEM (n = 3).
Figure 3. Drug sensitivity to gefitinib is associated with culture condition in YUO-004. A, Procedure for generating 2D PDOs. 3D PDOs were plated on collagen-coated plates and cultured in AO medium for more than a week up to 4 weeks. B, Comparison of IC50 values to each TKI (top) between 3D and 2D PDOs (two-tailed Student t test: n.s., not significant; **, P < 0.01; ***, P < 0.005). Red line denotes sensitive (IC50 value < 100 nmol/L) or resistant (IC50 value > 100 nmol/L) response to a drug. C, DNA chromatograms showing EGFR L747P mutation in 3D culture and 2D culture of YUO-050 and YUO-004. D, Scheme for model switching. 2D PDOs that were maintained as monolayer less than 4 weeks were switched to 3D culture condition and cultured for up to 4 weeks. All models were maintained in AO medium. E, 3D, 2D, and 2D–3D cultures of YUO-050 and YUO-004 were treated with the indicated concentrations of gefitinib for 3 days. IC50 value of gefitinib is indicated for each culture condition (top). F, Representative immunoblots of indicated molecules in YUO-050 and YUO-004 at baseline. G, Representative immunoblots of indicated molecules in YUO-050 and YUO-004 at baseline. H, 3D YUO-050 and YUO-004 were treated with dasatinib alone, gefitinib alone, or gefitinib in combination with the indicated concentrations of dasatinib for 3 days. I, Representative immunoblots of indicated molecules in YUO-004 treated with the indicated concentration of gefitinib with or without dasatinib. In B, E, and H, data are presented as the mean ± SEM (n = 3).CC BY-NC-ND · PubMed Central
Figure 4. PDOs recapitulate a clinical response to dabrafenib/trametinib combination therapy against EGFR exon 19 deletion plus BRAF G464A mutation. A, Summary of NGS analyses in liquid and tissue biopsies and YUO-071. B, CT scans showing tumor (red arrows) at disease progression to osimertinib (left) and after dabrafenib plus trametinib combination therapy (right) in a patient from which YUO-071 was generated. C, YUO-071 was treated with the indicated concentrations of osimertinib (far left), cetuximab (left), brigatinib with or without cetuximab at the indicated concentrations (right), and dabrafenib alone, trametinib alone, or trametinib plus dabrafenib at the indicated concentrations (far right) for 5 days. D, YUO-071 was exposed to osimertinib, dabrafenib, trametinib, dabrafenib plus trametinib, cetuximab, brigatinib, cetuximab plus brigatinib at the indicated concentrations for 15 days (left). Relative cell viability of YUO-071 before (day 0) and after the long-term exposure (day 15) to dabrafenib plus trametinib is shown on the right panel. E, Representative immunofluorescence images of indicated molecules in YUO-071 treated with control or 100 nmol/L dabrafenib in combination with 100 nmol/L trametinib for 5 days. Scale bar, 100 μmol/L. F, Bar graphs showing quantification of Ki-67–positive cells (left) and cleaved caspase 3–positive cells (right) in each group from E. In C, D, and F, data are presented as the mean ± SEM (n = 3; two-tailed Student t test). N/D, none detected.
Figure 4. PDOs recapitulate a clinical response to dabrafenib/trametinib combination therapy against EGFR exon 19 deletion plus BRAF G464A mutation. A, Summary of NGS analyses in liquid and tissue biopsies and YUO-071. B, CT scans showing tumor (red arrows) at disease progression to osimertinib (left) and after dabrafenib plus trametinib combination therapy (right) in a patient from which YUO-071 was generated. C, YUO-071 was treated with the indicated concentrations of osimertinib (far left), cetuximab (left), brigatinib with or without cetuximab at the indicated concentrations (right), and dabrafenib alone, trametinib alone, or trametinib plus dabrafenib at the indicated concentrations (far right) for 5 days. D, YUO-071 was exposed to osimertinib, dabrafenib, trametinib, dabrafenib plus trametinib, cetuximab, brigatinib, cetuximab plus brigatinib at the indicated concentrations for 15 days (left). Relative cell viability of YUO-071 before (day 0) and after the long-term exposure (day 15) to dabrafenib plus trametinib is shown on the right panel. E, Representative immunofluorescence images of indicated molecules in YUO-071 treated with control or 100 nmol/L dabrafenib in combination with 100 nmol/L trametinib for 5 days. Scale bar, 100 μmol/L. F, Bar graphs showing quantification of Ki-67–positive cells (left) and cleaved caspase 3–positive cells (right) in each group from E. In C, D, and F, data are presented as the mean ± SEM (n = 3; two-tailed Student t test). N/D, none detected.CC BY-NC-ND · PubMed Central
Figure 5. PDOs predict clinical activity of afatinib against EGFR L747P mutation. A, YUO-004 and YUO-050 were treated with the indicated concentrations of gefitinib, erlotinib, dacomitinib, afatinib, osimertinib, and lazertinib for 3 days. First-generation EGFR-TKIs are colored in dark, second-generation EGFR-TKIs are in red, and third-generation EGFR-TKIs are in blue. Data are presented as the mean ± SEM (n = 3). B, Representative immunoblots of indicated molecules in YUO-004 and YUO-050 treated with the indicated concentrations of gefitinib, afatinib, and osimertinib for 6 hours. C, Tumor growth curve of YUO-004 xenografts treated with indicated drugs at 25 mg/kg once daily (n = 6 per group; one-way ANOVA with Dunnett's posttest: n.s., not significant; **, P < 0.005 vs. vehicle; ##, P < 0.01 vs. afatinib). D, Immunoblots of indicated molecules in tumor samples obtained from YUO-004 xenografts treated with vehicle and 25 mg/kg gefitinib, afatinib, and osimertinib for 30 days.
Figure 5. PDOs predict clinical activity of afatinib against EGFR L747P mutation. A, YUO-004 and YUO-050 were treated with the indicated concentrations of gefitinib, erlotinib, dacomitinib, afatinib, osimertinib, and lazertinib for 3 days. First-generation EGFR-TKIs are colored in dark, second-generation EGFR-TKIs are in red, and third-generation EGFR-TKIs are in blue. Data are presented as the mean ± SEM (n = 3). B, Representative immunoblots of indicated molecules in YUO-004 and YUO-050 treated with the indicated concentrations of gefitinib, afatinib, and osimertinib for 6 hours. C, Tumor growth curve of YUO-004 xenografts treated with indicated drugs at 25 mg/kg once daily (n = 6 per group; one-way ANOVA with Dunnett's posttest: n.s., not significant; **, P < 0.005 vs. vehicle; ##, P < 0.01 vs. afatinib). D, Immunoblots of indicated molecules in tumor samples obtained from YUO-004 xenografts treated with vehicle and 25 mg/kg gefitinib, afatinib, and osimertinib for 30 days.CC BY-NC-ND · PubMed Central
Figure 6. PDOs can identify effective therapies for advanced lung adenocarcinoma harboring ERBB2 exon 20 insertions or RET rearrangements. A, YUO-046 and YUO-058 harboring ERBB2 exon 20 insertions were treated with the indicated concentrations of gefitinib, lapatinib, neratinib, afatinib, and poziotinib for 5 days. B, Representative immunoblots of indicated molecules in YUO-046 and YUO-058 treated with the indicated concentrations of gefitinib, lapatinib, neratinib, afatinib, and poziotinib for 6 hours. C, IC50 values of gefitinib, lapatinib, neratinib, afatinib, and poziotinib in YUO-053, a normal-like organoid, and tumor organoids harboring ERBB2 exon 20 insertions. D, Bar graphs showing mean relative IC50 values of the ERBB2 inhibitors in ERBB2-mutant organoids to the normal organoid. E, YUO-017 and YUO-049 harboring RET fusions were treated with the indicated concentrations of vandetanib, lenvatinib, cabozantinib, and pralsetinib for 5 days. F, Representative immunoblots of indicated molecules in YUO-017 and YUO-049 treated with the indicated concentrations of cabozantinib, pralsetinib, vandetanib, and lenvatinib for 2 hours. G, IC50 values of vandetanib, lenvatinib, cabozantinib, and pralsetinib in a normal-like organoid and tumor organoids harboring RET rearrangements. H, Bar graphs showing mean relative IC50 values of the RET inhibitors in RET fusion positive organoids to the normal organoid. In A and E, data are presented as the mean ± SEM (n = 3). In C and G, mean IC50 values were calculated from three biological replicates (three technical replicates per independent experiment) using GraphPad Prism. In D and H, data are presented as the mean ± SD (n = 2).
Figure 6. PDOs can identify effective therapies for advanced lung adenocarcinoma harboring ERBB2 exon 20 insertions or RET rearrangements. A, YUO-046 and YUO-058 harboring ERBB2 exon 20 insertions were treated with the indicated concentrations of gefitinib, lapatinib, neratinib, afatinib, and poziotinib for 5 days. B, Representative immunoblots of indicated molecules in YUO-046 and YUO-058 treated with the indicated concentrations of gefitinib, lapatinib, neratinib, afatinib, and poziotinib for 6 hours. C, IC50 values of gefitinib, lapatinib, neratinib, afatinib, and poziotinib in YUO-053, a normal-like organoid, and tumor organoids harboring ERBB2 exon 20 insertions. D, Bar graphs showing mean relative IC50 values of the ERBB2 inhibitors in ERBB2-mutant organoids to the normal organoid. E, YUO-017 and YUO-049 harboring RET fusions were treated with the indicated concentrations of vandetanib, lenvatinib, cabozantinib, and pralsetinib for 5 days. F, Representative immunoblots of indicated molecules in YUO-017 and YUO-049 treated with the indicated concentrations of cabozantinib, pralsetinib, vandetanib, and lenvatinib for 2 hours. G, IC50 values of vandetanib, lenvatinib, cabozantinib, and pralsetinib in a normal-like organoid and tumor organoids harboring RET rearrangements. H, Bar graphs showing mean relative IC50 values of the RET inhibitors in RET fusion positive organoids to the normal organoid. In A and E, data are presented as the mean ± SEM (n = 3). In C and G, mean IC50 values were calculated from three biological replicates (three technical replicates per independent experiment) using GraphPad Prism. In D and H, data are presented as the mean ± SD (n = 2).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Cited by

Sorted by citations

See all 151

Related

Metadata

Authors
Kim, S.-Y., Kim, S.-M., Lim, S., Lee, J. Y., Choi, S.-J., Yang, S.-D., Yun, M. R., Kim, C. G., Gu, S. R., Park, C., Park, A.-Y., Lim, S. M., Heo, S. G., Kim, H., & Cho, B. C.
Affiliations
  • Yonsei University (KR)
  • 3Interpark Bio Convergence Corp., Seoul, Korea.
Corresponding author
  • Heo, Seong Gu
  • Kim, HyunKi
  • Cho, Byoung Chul
ORCID
Venue
Clinical Cancer Research
Publisher
American Association for Cancer Research (AACR)
Published
2021-06-03
Volume
27
Issue
15
Pages
4397-4409
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
DOI
10.1158/1078-0432.ccr-20-5026
PMC
PMC9401503
OpenAlex
W3164073476
Cited by
151
References
56
Citations by year
2026: 26 · 2025: 35 · 2024: 39 · 2023: 28 · 2022: 19 · 2021: 4
FWCI
14.55
Type
journal article
Language
en
Open access
Licence
Locations
  • Clinical Cancer Research (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
Funders
  • Interpark bio Convergence
  • Ministry of Science and ICT, South Korea (2016R1A2B3016282)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
patient-derived organoids, advanced lung adenocarcinoma, non-small cell lung cancer, targeted therapy response prediction, tyrosine kinase inhibitors, dabrafenib/trametinib, EGFR exon 19 deletion, afatinib, poziotinib, pralsetinib, RET fusion, translational oncology
MeSH terms
Adenocarcinoma of Lung, Antineoplastic Agents, Humans, Lung Neoplasms, Models, Biological, Neoplasm Staging, Organoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review